cancer

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Therapeutics Inc. (NASDAQ: JUNO) shares continued to surge on Monday after Celgene Corp. (NASDAQ: CELG) had entered into an agreement to acquire Juno for a total of $9 billion or $87 per share. Juno shares rose 27 percent during Monday&rsq..

Insys co-founder Arrested on alleged Nationwide Opioid Scheme

Insys co-founder Arrested on alleged Nationwide Opioid Scheme

Co-Founder of Insys Therapeutics Inc. (NASDAQ: INSY) was arrested on Thursday by federal agents and charged with bribery, racketeering, and fraud to cause the illegal distribution of Fentanyl.John Kapoor was taken into custody in Phoenix, Arizona. K..

Spectrum shares surge on positive results from lung cancer treatment trial

Spectrum shares surge on positive results from lung cancer treatment trial

Spectrum Pharmaceutical Inc. (NASDAQ: SPPI) shares surged over 40 percent on Tuesday at open after its announcement of positive results from its Phase 2 clinical study of poziotinib. The announcement was presented at the 18th IASLC World Conference ..

National Institute of Health partners with 11 Biopharma companies for Cancer Research

National Institute of Health partners with 11 Biopharma companies for Cancer Research

The National Institutes of Health and 11 biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT). This is a five-year-public-private research collaboration totaling $215 million as part of the Cancer Moons..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca Shares fell on Disappointing Q2 Results and Cancer Study Results

AstraZeneca plc (NYSE: AZN) released a bevy of news today, including Q2 results, as well as study results for two drugs. AZN price has plummeted 15%.Following the loss of exclusivity for Crestor and Seroquel XR AstraZeneca had expected losses in the..